Skip to main content
  • News in Review

    Reusing Some Supplies May Trim Costs

    Download PDF

    This month, News in Review highlights selected papers from the original papers sessions at AAO 2023. Each was chosen by an Annual Meeting Program Committee subspecialty chair because it presents important news or illustrates a trend in the field. Only four subspecialties are included here; papers sessions will also be held in five other fields. For more information, see the Mobile Meeting Guide (aao.org/mobile).


    Reusing gonioscopy and tonom­etry supplies can lead to substantial cost savings, according to new research by scientists at Columbia University Irving Medical Center. The total savings for the average ophthalmology practice associated with reusing these supplies tallied nearly $122,000 over one year and $1,225,000 over 10 years.

    “This study highlights significant excess cost and waste generation in ophthalmology that is insidiously becoming common practice,” said lead investigator Alexis Kassotis, MD, at Columbia University Medical Center. The savings associated with reusable ophthalmology equipment could be redirected to support patient care and other aspects of practice, she said.

    Prisms of the Goldmann-type applanation tonometer create blue, glowing semicircles in front of a black background.

    PRISMS. Semicircles of the Goldmann-type applanation tonometer.

    Study approach. The researchers wanted to evaluate and compare costs associated with disposable and reusable ophthalmological devices, and they chose to focus on gonioscopy lenses and tonometry tips because both reus­able and disposable versions of these are used in the United States, making a cost analysis and comparison possible.1 The team used scenario analysis to estimate the cost of using disposable and reusable gonioscopy lenses and tonometry tips over one, five, and 10 years at a single medical center.

    The brands used included iCare IC100 rebound tonometer and tips, Haag-Streit Goldmann applanation to­nometry prisms, Tono Safe disposable tips, Volk reusable gonioscopy lenses, and Katena disposable gonioscopy lens­es. Assuming all of these brands were available, Dr. Kassotis said, “The mean cost of all commonly used devices was calculated.” For reusable tonometry tips and gonioscopy lenses, the cost of sanitation after each use and the need for replacement every few years—due to device dysfunction or loss and waste—was taken into account, said Dr. Kassotis.

    Findings. Over the course of one year, reusing tonometry tips saved $97,037 compared to disposables, yielding an 89.9% cost savings. Adop­tion of reusable gonioscopy lenses saved $24,907 over one year, a 66.0% cost savings compared to disposable lenses. Over 10 years, using reusable tonometry tips saved $908,368 and using reusable gonioscopy lenses saved $316,275—a 96.5% and 91.6% cost savings, respectively.

    Cost savings for reusable applanation tonometry prism tips and gonioscopy lenses combined led to an estimated total savings of $121,944 over a year’s time. After a decade, the savings ballooned to more than $1.2 million. “A single disposable tonometry tip or gonioscopy lens is cheap. However, the cumulative cost of disposable devices is far greater than that of reusable ver­sions because reusable options can be sanitized and reused many times,” Dr. Kassotis said.

    A potential drawback to reusable equipment is the theoretical risk of con­tact with mucous membranes and the spread of infection, said Dr. Kassotis. She added, however, that there is no high-quality evidence that reusable de­vices, when properly sanitized, increase infection transmission.

    Additional considerations. Although this study focused solely on cost, both infection control and ease of use should be factors when choosing between disposable and reusable equipment, she said, adding, “The environmental impact of disposable devices should also be considered.”

    —Christos Evangelou, PhD

    Reusable Gonioscopy Lenses and Tonometry Tips Are Associated With Signif­icant Potential Cost Savings (Pa064). When: Monday, Nov. 6, 10:21-10:28 a.m., during the glaucoma original papers session (9:45-11:00 a.m.). Where: West 2006. Access: AAO 2023 registration.

    ___________________________

    1 Junk AK et al. J Glaucoma. 2020;29(7):507-512.

    ___________________________

    Relevant financial disclosures: Dr. Kassotis—None.

    For full disclosures and the disclosure key, see below.

    Full Financial Disclosures

    Dr. Koo Emmecell: S.

    Ms. Shaia Cleveland Eye Bank Foundation: S; Clinical and Translational Science Collaborative of Cleveland, funded by the National Institutes of Health: S; National Center for Advancing Translational Sciences: S; NEI: S; Research to Prevent Blindness: S.

    Dr. Subramanian GenSight Biologics: C,S; Horizon: C,S; Invex Therapeutics: C; Kriya Therapeutics: C; Santhera Pharmaceuticals: S; Viridian Therapeutics: C.

    Dr. Kassotis None.

    Dr. Watane None.

    Disclosure Category

    Code

    Description

    Consultant/Advisor C Consultant fee, paid advisory boards, or fees for attending a meeting.
    Employee E Hired to work for compensation or received a W2 from a company.
    Employee, executive role EE Hired to work in an executive role for compensation or received a W2 from a company.
    Owner of company EO Ownership or controlling interest in a company, other than stock.
    Independent contractor I Contracted work, including contracted research.
    Lecture fees/Speakers bureau L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Patents/Royalty P Beneficiary of patents and/or royalties for intellectual property.
    Equity/Stock/Stock options holder, private corporation PS Equity ownership, stock and/or stock options in privately owned firms, excluding mutual funds.
    Grant support S Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
    Stock options, public or private corporation SO Stock options in a public or private company.
    Equity/Stock holder, public corporation US Equity ownership or stock in publicly traded firms, excluding mutual funds (listed on the stock exchange).

     

    More from this month’s News in Review